Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04559230
Other study ID # CTMS# 20-0102
Secondary ID HSC20200576X
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 6, 2022
Est. completion date February 2025

Study information

Verified date March 2024
Source The University of Texas Health Science Center at San Antonio
Contact Epp Goodwin
Phone 210-450-1000
Email goodwine@uthscsa.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label single arm study. All patients will receive the investigational agent.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date February 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee - Histologically confirmed IDH wild-type (de novo) GBM - Progression following standard combined modality treatment with radiation and temozolomide chemotherapy if O6-Methylguanine-DNA Methyltransferase (MGMT) methylated; prior temozolomide is not required for MGMT unmethylated, but patient must have received standard doses of radiation. Inclusion of additional investigational therapy with standard therapy is not exclusionary. No additional lines of therapy. - Patients may have had been operated for recurrence, but if operated must have had surgery a minimum of 2 weeks prior to enrollment and have an MRI completed within 48 hours following surgery. - No radiotherapy within the three months prior to the diagnosis of progression. - Willingness to forego tumor treatment field (Optune) therapy during participation in the study. - Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan. - Recovered from toxicities of prior therapy to grade 0 or 1, except for neuropathy (=Grade 2) and alopecia. - ECOG performance status = 2 - Life expectancy of at least 6 months - Acceptable liver function: 1. Bilirubin = 1.5 times upper limit of normal 2. AST (SGOT) and ALT (SGPT) = 3.0 times upper limit of normal (ULN); - Acceptable renal function: a. creatinine clearance =30 mL/minute according to the Cockcroft and Gault formula - Acceptable hematologic status (without hematologic support): 1. ANC =1500 cells/uL 2. Platelet count =100,000/uL 3. Hemoglobin =9.0 g/dL - All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose - Availability of biological material for central review and biomarker evaluation Exclusion Criteria: - Prior treatment with bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling inhibitors - The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug. - The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible. - The subject is unable to undergo MRI scan (eg, has pacemaker). - The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone). - The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade = 1 from AEs (except alopecia, anemia and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other medications that were administered prior to study drug. - The subject is pregnant or breast-feeding. - The subject has serious intercurrent illness, such as: - hypertension (two or more blood pressure [BP] readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment - non-healing wound, ulcer, or bone fracture - significant cardiac arrhythmias - untreated hypothyroidism - unhealed rectal or peri-rectal abscess - uncontrolled active infection - symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug any history of cardiac arrhythmia or heart block - stroke or transient ischemic attack within 6 months - The subject has received any of the following prior anticancer therapy: - Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed - Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior first dose of study drug - Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug - Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug - Prior treatment with carmustine wafers - Patients with radiographically apparent leptomeningeal involvement are excluded

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sacituzumab Govitecan
Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.

Locations

Country Name City State
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States Texas Oncology Dallas Texas
United States University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival A single-arm two-stage Phase II Bayesian adaptive study of Sacituzumab Govitecan will be carried out in the expansion phase based on progression free survival at 6 months with unfavorable and favorable probabilities of 0.17 and 0.34, respectively. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs